Garditam Solution

It shows Anti-Epileptic by binding to a unique synaptic vesicle protein 2A (SV2A). SV2A protein is a part of secretory vesicle membranes that mediates calcium-dependent vesicular neurotransmitter release. The binding of levetiracetam to SV2A appears to decrease the rate of vesicle release.

Indications:

• Myoclonic seizures
• Partial onset of seizures
• Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy
• Status Epilepticus & Seizure Prophylaxis In Subarachnoid Haemorrhage
• Seizures in Palliative Care

Dosage & Administration:

Partial Onset Seizures

• 1 Month to < 6 Months: 7 mg/kg twice daily; increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily
• 6 Months to < 4 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily
• 4 Years to < 16 Years: 10 mg/kg twice daily; increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily

Myoclonic Seizures in Paediatric Patients 12 Years and Older

• 500 mg twice daily; increase by 500 mg twice daily every 2 weeks to recommended dose of 1500 mg twice daily

Primary Generalized Tonic-Clonic Seizures

• 6 Years to < 16 Years: 10 mg/kg twice daily, increase in increments of 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily

HOW SUPPLIED: GARDITAM SYRUP is available as Oral Solution in 100ml Pack.